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impact of all therapies indicated for ultra-orphan disorders, which might be an 
important consideration for future models.  
 
PCN30  
ESTIMATING DEVELOPMENT COST OF AN INTERACTIVE WEBSITE BASED 
CANCER SCREENING PROMOTION PROGRAM  
Chung TH1, Lairson DR1, Smith LG2, Champion VL3 
1University of Texas School of Public Health, Houston, TX, USA, 2Ball State University, Muncie, 
IN, USA, 3Indiana University, Indianapolis, IN, USA  
OBJECTIVES: The aim of this study is to estimate the development costs of a 
tailored intervention delivered via the interactive web, designed to increase 
cancer screening in women 51 to 75 who are non-adherent to colorectal cancer 
(CRC) and may or may not be adherent to breast cancer screening. METHODS: 
The cost of the intervention development is estimated from a societal 
perspective. Micro costing methods plus vendor contract costs were used to 
estimate the intervention development cost. Staff logs were used to track 
personnel time. Non-personnel costs include all resources used to produce the 
intervention. RESULTS: Development cost of the interactive web based 
intervention is $0.39 million, of which 77% is direct cost. About 98% of the cost 
was incurred in personnel time cost, contract cost and overhead cost. Eighteen 
persons contributed a total of 1610 hours to intervention development. 
CONCLUSIONS: The new web-based disease prevention medium requires 
substantial investment of health promotion and media specialist time. As health 
promotion and disease prevention programs move to the internet, it is important 
to assess development and intervention costs along with program impacts on 
health behaviors and outcomes. The cost of intervention development is 
important for planning future investments in web-based health promotion 
interventions and also relevant to the private sector investment and pricing 
decisions for new health promotion products and services.  
 
PCN31  
ADHERENCE TO AND COSTS OF LIFE EXTENDING THERAPIES FOR METASTATIC 
CASTRATE-RESISTANT PROSTATE CANCER  
Spalding J1, Bui CN1, Burton TM2 
1Astellas Pharma US, Inc., Northbrook, IL, USA, 2OptumInsight, Waltham, MA, USA  
OBJECTIVES: Life extending therapies (LETs) for metastatic castrate-resistant 
prostate cancer (mCRPC) increase overall survival. This study examined 
adherence to LETs and concomitant corticosteroids, and health care costs. 
METHODS: A retrospective claims study of commercial and Medicare Advantage 
enrollees with evidence of prostate cancer (ICD-9: 185.xx) between July 1, 2006 – 
June 30, 2011. mCRPC patients were identified based on evidence of LET use: 
docetaxel (DOC), cabazitaxel (CAB), and/or abiraterone acetate (ABI). The index 
date was the first date of chemotherapy. Patients were continuously enrolled for 
6 months before (baseline) and ≥6 months after the index date until December 
31, 2011 or death (follow-up). Adherence was defined as the proportion of days 
covered (PDC). Costs were the sum of health plan- and patient-paid amounts. 
Descriptive statistics summarized PDC and costs during follow-up. RESULTS: A 
total of 1,198 patients had ≥1 LET (DOC: 1,196, CAB: 27, ABI: 109). Mean±SD age 
was 69±9 years. Average PDC for LET was: DOC: 0.91, CAB: 0.88, ABI: 0.96. Half or 
more had a concomitant corticosteroid: DOC: 552, CAB: 17, ABI: 99, with an 
average PDC of: DOC 0.57, CAB 0.62, ABI 0.74. Average±SD cumulative 12-month 
health care costs were $76,550±$82,485. Average±SD per-patient-per-month 
(PPPM) health care costs during LET were higher for patients with a concomitant 
corticosteroid than those without: $9,307±$7,436 versus $5,929±$11,103; p<0.001. 
Patients with high adherence to a concomitant corticosteroid (PDC≥80%) had 
higher average PPPM costs during LET than patients with lower adherence 
(PDC<80%) or without: $9,028±$7,133 versus $7,339±$9,992; p=0.002. 
CONCLUSIONS: mCRPC patients had high adherence to LET but lower adherence 
to indicated concomitant corticosteroid. Average PPPM costs were higher for 
patients with greater adherence to concomitant corticosteroids than patients 
with lower adherence or no use. Multivariate analyses are planned to better 
understand the association between corticosteroid adherence during LET use 
and costs. The database timeframe did not allow for the inclusion of newer 
therapies.  
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ECONOMIC BURDEN OF ADVERSE EVENTS IN PATIENTS AGED ≥65 YEARS 
RECEIVING TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)  
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OBJECTIVES: To estimate costs associated with adverse events (AEs) in patients 
aged ≥65 years receiving treatment for mRCC. METHODS: Retrospective study 
using the linked SEER (Surveillance, Epidemiology and End Results) Medicare 
database. Study subjects consisted of all persons in the linked SEER-Medicare 
database, aged ≥65 years, with evidence of newly diagnosed mRCC between 
January 1, 2007 and December 31, 2007. AEs of interest comprised abdominal 
pain, back pain, diarrhea, dyspnea, extremity pain, fatigue/asthenia, hand-foot 
syndrome, hypertension, lymphopenia, nausea/vomiting, neutropenia, and 
proteinuria. Patients receiving care for these AEs were identified using ICD-9-CM 
diagnosis codes on Medicare claims. Costs were examined over a 30-day period, 
beginning with date of first mention of each AE; non-evented patients were 
assigned a “shadow” index date for comparison purposes. We estimated total 
costs over 30 days following the index date for patients with and without AEs, on 
both an unadjusted basis and following adjustment for differences in baseline 
characteristics using a generalized linear model (GLM). RESULTS: Sixty percent of 
patients receiving treatment for mRCC had health care encounters for one or 
more AEs. Those occurring 20% or greater frequency included severe abdominal 
pain, dyspnea, and fatigue/asthenia; 10-20% of patients had encounters for back 
pain, extremity pain, and nausea/vomiting. Mean (SD) total costs of care during 
the 30-day, post-index period were substantially higher among patients with AEs 
($13,944 [$14,529] versus $1,878 [$5,264] for those without these events). 
Adjusting for differences in baseline characteristics, the estimated cost 
difference (95% CI) was $11,454 ($7,909 - $16,319). CONCLUSIONS: Costs of AEs 
associated with treatment of mRCC are high in patients aged ≥65 years. Efforts to 
prevent and/or better manage these events may reduce health care costs.  
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THE COSTS OF ORAL VERSUS INTRAVENOUS CHEMOTHERAPY IN INSURED, 
LOW INCOME PATIENTS WITH BREAST OR COLON CANCER  
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1University of South Carolina, Columbia, SC, USA, 2University of South Carolina, Greenville, SC, USA  
OBJECTIVES: As oral chemotherapy is becoming more prevalent in treating 
cancer patients, the cost difference between oral and conventional intravenous 
(IV) chemotherapy is not clear. The objective of this study was to compare the 
total costs of oral chemotherapy and IV chemotherapy in insured, low- income 
patients with breast cancer or colon cancer using South Carolina (S.C.) Medicaid 
claims data. METHODS: Patients with breast or colon cancer and receiving oral 
chemotherapy (capecitabine and oral cyslophosphamide) or conventional IV 
chemotherapy (5-FU and cyclophosphamide) were identified from S.C. Medicaid 
for years 2006-2009. Total costs, including inpatient, outpatient and prescription 
drugs, for one year follow-up period after initiation of chemotherapy were 
calculated. A multiple linear regression model with log transformation was used 
to examine the association between total costs and chemotherapy (oral vs. IV). 
RESULTS: A total of 1219 patients (857 for breast cancer, 362 for colon cancer) 
were identified from S.C. Medicaid claims data for years 2006-2009. The 
unadjusted annual total costs were $45,535(oral) and $59,498 (IV, p<0.001) for 
breast cancer, and $50,385 (oral) and $56,347 (IV, p=0.274) for colon cancer. Oral 
chemotherapy was associated with 36% and 43% reduction in cost for Medicaid 
breast and colon cancer patients respectively after adjusting for confounders. 
CONCLUSIONS: Total cost savings might be achieved in insured, low- income 
patients receiving oral chemotherapy to treat breast and colon cancers. Further 
studies are needed to link the costs to clinical outcomes and adverse drug events 
associated with chemotherapy.  
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CHARGES ASSOCIATED WITH CHEMOTHERAPY INDUCED NAUSEA AND 
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OBJECTIVES: Chemotherapy induced nausea and vomiting (CINV) has clinical 
and economic implications. Controlling CINV upon chemotherapy initiation is 
important as the likelihood of CINV in future chemotherapy cycles increases if a 
patient experiences CINV in the first/previous chemotherapy cycle. The purpose 
of this study was to evaluate economic implications of 5-HT3-RA selection on 
CINV charges. METHODS: A retrospective analysis was conducted utilizing 
medical and pharmacy claims from 2005-2011 from a commercial (96%) and 
Medicaid (4%) population. Continuously enrolled patients (6 month pre-period, 6 
month post-period) with cancer receiving single-day chemotherapy regimens 
were eligible. Patients had to remain on initial 5-HT3-RA therapy and same level 
of emetic potential of chemotherapy throughout the study. CINV was defined as 
primary/secondary diagnosis of nausea, vomiting, or dehydration based on ICD-9 
codes, or use of rescue antiemetic medication. Charges for CINV were captured 
for an overall random sample of 1,000 for each chemotherapy cycle. A charge per 
patient was calculated and used to calculate an average charge for all patients in 
each 5-HT3-RA cohort based on the percentage of patients in each cycle 
experiencing CINV. Patients without CINV in the previous cycle or who switched 
5-HT3-RA therapy were excluded from subsequent calculations. RESULTS: 
Patients receiving palonosetron had lower rates of CINV across chemotherapy 
cycles compared to ondansetron, granisetron, or dolasetron. Patients receiving 
palonosetron had the lowest charges associated with CINV with a total of 
$300,293 over 6 cycles of chemotherapy. Patients receiving granisetron incurred 
the highest charges at $470,131 over 6 cycles. The use of palonosetron has the 
potential to result in a savings of $126,775 (vs ondansetron) to $169,838 (vs 
granisetron), depending on 5-HT3-RA selection. CONCLUSIONS: Patients 
receiving palonosetron experienced lower CINV-associated charges for each 
cycle of chemotherapy. Selection of 5-HT3-RA has the ability to positively impact 
economic outcomes associated with CINV.  
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COMPARATIVE ANALYSIS OF RADIUM-223 VERSUS PLACEBO IN 
SYMPTOMATIC METASTATIC CASTRATION RESISTANT PROSTATE CANCER 
TREATED WITH BEST STANDARD OF CARE ON SKELETAL-RELATED EVENTS 
OUTCOMES  
Seal B1, Pawar V2, Valderrama A3, Grabbi E4, Lloyd A4, Beaudet A5 
1Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, USA, 2Bayer Healthcare 
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OBJECTIVES: Radium-223 dichloride (Ra-223) is a novel alpha-
radiopharmaceutical, which delayed time to first skeletal-related event (SRE) and 
improved overall survival versus best standard of care (BSoC) in patients with 
symptomatic castration-resistant prostate cancer (mCRPC) with bone 
metastases. This analysis evaluated economic benefits associated with Ra-223. 
METHODS: A Markov model was developed using patient-level data from  
a pivotal trial in which mCRPC patients receiving BSoC were randomized 2:1 to 
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Ra-223 or placebo respectively. Patients entered the model progression-free, 
receiving active treatment until progression or completion of the therapy course. 
Health states reflected patients experiencing first or subsequent SRE. In the trial, 
SRE was defined as treatment with external-beam radiation therapy (EBRT), 
surgical intervention, occurrence of pathological bone fracture, or spinal cord 
compression. A 5-year time horizon was considered. Costs were estimated from 
a US payer perspective. SRE costs were obtained by multiplying the number  
of patients experiencing SRE by its specific treatment cost (including 
hospitalization costs). RESULTS: Ra-223 increased mean life expectancy by 0.325 
(95% CI: 0.324-0.326) years in the ITT population and 0.517 (95% CI: 0.516-0.518) 
years in the subgroup of patients who had not received first-line docetaxel.  
Ra-223 was projected to lead to 44% reduction in the cost of treatment of SREs 
versus BSC: 46% reduction in pathologic bone fracture costs; 48% for spinal  
cord compression; 16% for external beam radiation; and 11% for  
surgical interventions. A total of 32.9% of patients suffered a first SRE for Ra-223 
versus 37.8% for placebo and 6.5% and 7.8%, respectively, suffered two or more 
SRE events. CONCLUSIONS: In patients treated with BSoC, Ra-223 reduced  
costs of SREs. Future studies will evaluate the total cost of care related to  
the benefit of Ra-223 versus placebo in patients treated with BSoC in  
mCRPC once the cost of therapy and the impact on quality adjusted survival are 
known.  
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COST ANALYSIS MODEL BETWEEN THE COBAS BRAF TEST AND SANGER 
SEQUENCING WHEN TREATING MALIGNANT MELANOMA BASED ON THE 
PRESENCE OF V600 MUTATIONS  
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OBJECTIVES: Validated companion diagnostic assays permit collection of critical 
clinical data that leads to actionable treatment decisions and better patient 
outcomes. The cobas BRAF test is an FDA-approved companion diagnostic that 
identifies V600 mutation positive malignant melanoma to determine patient 
eligibility for treatment with vemurafenib. Sanger sequencing is also a validated, 
lab developed test that provides similar information for the gene encoding the 
BRAF protein. Test performance differences can have an impact on patient 
outcomes and overall cost of testing and treatment. METHODS: Based on assay 
performance data for both tests, generated during the phase 2 BRIM-2 (N=132), 
BRIM-2/3 (N=433) and phase 3 BRIM-3 (N=449) studies, an integrated drug-
diagnostic budget impact model was developed from a third-party payer 
perspective assuming a 6-month treatment period. Cost estimates were based on 
testing 100% unresectable stage III-IV melanomas assuming 50% incidence of 
BRAF mutations. Diagnostic costs were based on reimbursement for average 
code-stacks across various lab and therapeutic costs for vemurafenib (and 
ipilimumab) were inclusive of administrative and adverse event costs. Sensitivity 
models were run to estimate costs across a wide range of values for the various 
model parameters. RESULTS: Overall, the sum of invalid tests, false positive and 
false negative results across all 3 studies was 14.6% (148/1014) for Sanger 
sequencing and 0.6% (6/1014) for the cobas BRAF test. Use of the cobas BRAF test 
versus Sanger sequencing resulted in total saving of $14.2 million or $1,479.17 
per patient in the BRIM-3 study and $21.9 million or $2,281.25 per patient in the 
BRIM2/3 dataset. Savings were primarily a result of avoiding unnecessary or 
inappropriate drug therapy and diagnostic costs accounted for a small fraction 
(0.13-0.29%) of total expenditures. CONCLUSIONS: Use of the clinically validated 
and more accurate cobas BRAF test resulted in significant cost savings relative to 
Sanger sequencing for BRAF mutations.  
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IFOSFAMIDE TREATMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: 
HEALTH CARE UTILIZATION AND COST IMPLICATIONS  
Engel-Nitz NM, Song R, Horstman TV 
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OBJECTIVES: Ifosfamide, a key chemotherapy for advanced stages of the  
rare cancer soft-tissue sarcoma (STS), is a generic medication. However, 
administration often entails hospitalization and adjuvant mesna as prophylaxis 
against hemorrhagic cystitis; resultant costs are unknown. This study examined 
health care costs and its drivers for managed care patients with STS who were 
treated with ifosfamide and other chemotherapies. METHODS: We 
retrospectively studied administrative claims of adult STS patients in a large US 
managed care plan who initiated chemotherapy between 2000−2011. The first 
chemotherapy treatment following diagnosis identified in medical claims was 
categorized by setting of chemotherapy initiation (ambulatory or hospital). 
Health care utilization and costs were identified over a 1-year follow-up 
(retaining patients dying prior to 1 year); patient/clinical characteristics were 
assessed over a 6-month baseline. Analyses included descriptive statistics and 
ordinary least squares on logged costs adjusted for patient/clinical 
characteristics (retransformed with smearing estimator). RESULTS: Ifosfamide-
treated patients (alone, n=18, or combined with doxorubicin, n=47) were younger 
compared to the 149 patients in 4 other chemotherapy cohorts: means 50-52, 
versus 58 years for the next youngest (doxorubicin, gemcitabine+docetaxel 
cohorts), p=0.004. Total health care costs were significantly higher for ifosfamide 
cohorts (adjusted means $ 115,559 and $ 129,537) versus other cohorts except for 
gemcitabine+docetaxel (means ranged from $73,496 to $117,451, p<0.05). 
Differences in medical costs were due to higher ambulatory and inpatient 
expenditures for ifosfamide cohorts, which generally had higher numbers of 
visits including inpatient visits: ifosfamide means 0.94, 1.49, versus other cohorts 
0.65, 0.72, 0.81, and 1.51 (gemcitabine+docetaxel), p<0.016. CONCLUSIONS: 
Patients with STS treated with ifosfamide had significantly higher health care 
costs than did patients treated with most other chemotherapies, suggesting that 
although a generic medication, ifosfamide may impose a higher disease 
management burden and impact on health plan budgets. Whether emerging 
therapies will result in lower health care costs warrants exploration.  
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OBJECTIVES: Incidence of hepatocellular carcinoma (HCC) is increasing in the 
U.S. and worldwide. Several treatments are available for patients newly 
diagnosed with the disease. We examine cumulative Medicare-paid expenditures 
and survival associated with various treatment modalities for HCC in a 
population for which it is most treated. METHODS: Medicare enrollees with an 
initial diagnosis of primary HCC between 2000-2007 were followed through 2009. 
Data are from SEER and linked Medicare databases, with claims generated from 
Parts A and B. Multivariate Cox proportional hazards models were used to 
estimate risk and calculate mean all-cause/HCC-related survival associated with 
transplant, resection, liver directed therapy, radiation, systemic chemotherapy 
or no treatment. Partitioned inverse probability-weighted least squares 
regression estimated cumulative Medicare expenditures adjusted for censoring 
and covariates. Bootstrapping was used to obtain 95% Confidence Intervals for 
cost estimates. RESULTS: Cancer stages one, two, three and four represented 
24%, 9%, 14%, and 17% of the 11,047 patients, respectively. Nearly one-third (37%) 
were unstaged, 66% were male, 75% Caucasian, 10% African American; 60% of 
patients were untreated, 16% liver directed, 8% chemotherapy, 8% resection, 4% 
radiation, and 4% transplant. Using all-cause (HCC-related) mortality, transplant 
patients incurred an average $263,296 [95%CI: $244,200-$282,392] over an average 
5.47 (6.9) years, resection $131,812 [$126,770-$136,854] over 3.5 (5.1) years, liver 
directed $91,488 [$88,749-$94,227] over 2.2 (3.8) years, chemotherapy $55,379 
[$53,442-$57,316]over 1.2 (2.8) years, radiation $58,308 [$55,355-$61,261] over 1.2 
(2.6) years, and no treatment $27,937 [$27,355-$28,519] over 0.6 (1.1) years. 
CONCLUSIONS: Cumulative Medicare expenditures were over 9x higher for 
transplant versus no treatment, nearly 5x for resection, over 3x for liver directed, 
and nearly double for chemotherapy or radiation, even after adjusting for cancer 
stage and other confounders. Differences in Medicare spending between 
treatment modalities were nearly proportional to differences in (all-cause) years 
survived after HCC diagnosis.  
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REAL-WORLD DATA ANALYSIS OF COLORECTAL CANCER (CRC) TREATMENT 
WITH BIOLOGIC DRUGS IN A MEDICAL COOPERATIVE IN BRAZIL  
Santos MCL, Maturana MS 
Unimed São José do Rio Preto, São José do Rio Preto, Brazil  
OBJECTIVES: Colorectal cancer is the third highest incidence amongst all cancers 
worldwide. Biologics are increasingly used as a treatment option, and due to 
high associated drug cost HMOs need to minimize expenditures by choosing less 
costly treatment strategies. Real-world data is growing in importance in health 
care decision making especially in coverage and reimbursement decisions. 
Therefore, the objective of the study is support treatment decision making by 
providing evidence based on real-world data, focusing on most used biologics in 
metastatic CRC: bevacizumab and cetuximab. METHODS: A review of 
administrative claims database of Unimed São José do Rio Preto (medical 
cooperative responsible for 118,000 lives in São Paulo-Brazil) was conducted for 
patients who underwent CRC treatment between December 2009 through 
January 2012. In order not to disclose confidential commercial arrangements 
with suppliers analysis were focused on total costs of treatment (drugs, 
devices/materials and room taxes). In the cases where a single patient 
underwent treatment with more than one biologic the analysis was performed 
considering the different regimens for the patient, obtaining daily 
costs/regimen/patient, and then converted on monthly basis. Focus was given to 
costs related to bevacizumab plus chemotherapy (Bev+CT) and cetuximab plus 
chemotherapy (Cet+CT) regimens. Also, regimens were classified into irinotecan 
or oxaliplatin-based. Costs were reported in Brazilian Reais (BRL1.00~USD0.48 
December 2012). RESULTS: A total of 108 CRC patients were identified and 
regimens were 22.7% Bev+CT and 16.3% Cet+CT. Approximately 80% of both 
biological drugs were combined with irinotecan-based schemes. Average 
cost/patient/month were BRL 12,585 (SD: BRL3,588) for Bev+CT and BRL 17,178 
(SD: BRL3,797) for Cet+CT. CONCLUSIONS: Results indicate potential resource 
savings favoring bevacizumab. If all patients treated with cetuximab were 
treated with bevacizumab instead, it could averagely result in savings of BRL 
64,301 per month (less 26.7%). Study had limitation regarding identification of 
treatment line and sample size precluded identification of statistical difference 
between treatments.  
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COST EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AS TREATMENT 
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SWEDEN  
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OBJECTIVES: Abiraterone acetate (AA), a selective androgen biosynthesis 
inhibitor, blocks the action of CYP17, thereby inhibiting adrenal and intratumoral 
